{"id":"bivalent-rbd-based-arvac-cg-vaccine","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The Bivalent RBD-based ARVAC-CG vaccine is a vaccine that targets the receptor-binding domain (RBD) of SARS-CoV-2, eliciting a strong immune response against the virus.","oneSentence":"ARVAC-CG vaccine targets the RBD of SARS-CoV-2","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:24:39.887Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19"}]},"trialDetails":[{"nctId":"NCT05752201","phase":"PHASE2, PHASE3","title":"ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine","status":"COMPLETED","sponsor":"Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno","startDate":"2023-02-06","conditions":"COVID-19 Vaccine","enrollment":2014}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Bivalent RBD-based ARVAC-CG vaccine","genericName":"Bivalent RBD-based ARVAC-CG vaccine","companyName":"Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno","companyId":"centro-de-educaci-n-medica-e-investigaciones-cl-nicas-norberto-quirno","modality":"Biologic","firstApprovalDate":"","aiSummary":"ARVAC-CG vaccine targets the RBD of SARS-CoV-2 Used for COVID-19.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}